Knock-down of MVP reduced cell growth and induced apoptosis in CS cells, and combined inhibition of MVP and GLI1 significantly suppressed CS progression in vitro and in vivo, suggesting MVP is a potential target therapeutic strategy for advanced CS [112]. This evidence concerns the gene GLI1 and Cowden syndrome 1.